Clearside falls on Phase II DME data

Clearside Biomedical Inc. (NASDAQ:CLSD) lost $4.68 (32%) to $9.86 on Thursday after reporting that suprachoroidal CLS-TA plus Eylea aflibercept led to a smaller gain in visual acuity and a greater incidence of both elevated intraocular pressure and cataracts compared with Eylea alone in the Phase II TYBEE trial to treat diabetic macular edema.

The double-blind, U.S. trial enrolled 71 treatment-naïve patients to receive CLS-TA plus intravitreal Eylea at months zero and three, or four monthly treatments of Eylea. Patients in both arms could receive Eylea at months four and five as needed. CLS-TA is a suspension of triamcinolone acetonide delivered using Clearside's suprachoroidal space microinjector...